United States Neurotherapeutics Industry Analysis 2025 | Market Size, Growth Drivers & Emerging Players

Neurotherapeutics market size reached US$7.28Billion in 2024 from US$6.97Billionin 2023 and is expected to reach US$ 11.10Billion by 2033, growing at a CAGR of 4.9%during the forecast period 2025-2033.

DataM Intelligence unveils its latest report on the "Neurotherapeutics Market Size 2025," offering an in-depth analysis of market trends, growth drivers, competitive landscape, and regional dynamics. The study covers market size in value and volume, CAGR forecasts, and emerging opportunities that can guide businesses in seizing growth potential and crafting winning strategies. Packed with data-driven insights on current developments and future trends, this report is essential for companies aiming to stay ahead in the competitive Market.

Latest M&A

Johnson & Johnson acquired Intra-Cellular Therapies for $14.6 billion (July 2025), adding the CNS drug Caplyta and pipeline assets in schizophrenia, bipolar depression, and Alzheimer's disease.

Novartis completed a deal worth up to $1.7 billion to acquire Regulus Therapeutics, expanding its microRNA-based neurological therapeutics portfolio

Supernus acquired Sage Therapeutics for $561 million upfront and up to $234 million in milestone payments, gaining FDA-approved zurzuvae for postnatal depression and a CNS-focused drug pipeline

Eli Lilly acquired SiteOne Therapeutics for up to $1 billion in cash; the lead compound, a Nav1.8 pain inhibitor, will bolster Lilly's neurology pipeline (Q3 2025).

Sanofi closed its acquisition of Vigil Neuroscience for $470 million cash plus up to $130 million in milestones, expanding its Alzheimer's and neuroinflammation franchises

Atai Life Sciences acquired Beckley Psytech for $390 million in shares and $30 million in private placement, consolidating psychedelic neurology therapies

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/neurotherapeutics-market?kb

Key Market Highlights

North America leads the neurotherapeutics market with a 44.09% revenue share in 2024.

Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 5.9%.

By treatment type, neurological drugs dominate with a 58.73% revenue share in 2024.

Leading players include Medtronic, Boston Scientific, Abbott, Aleva Neurotherapeutics, NeuroPace, Biogen, Novartis, Teva, Eli Lilly, and Johnson & Johnson.

List of Top Key Player:

Medtronic, Boston Scientific Corporation, Abbott, Aleva Neurotherapeutics, NeuroPace, Inc., Biogen, Novartis AG, Teva Pharmaceutical Industries Ltd, Eli Lilly and Company, andJohnson & Johnson, among others.

Latest Investments

Draig Therapeutics raised $140 million Series A in June 2025 for depression and GABA-A receptor drug programs; GRIN Therapeutics secured $140 million (May 2025) for NMDA receptor therapies.

Venture funding sustained major late-stage neuro startups: Neurona Therapeutics ($102M in April), Neuron23 ($97M in June), Vima Therapeutics ($60M in May 2025) to advance clinical assets in neuroregeneration, NEULARK Parkinson's, and dystonia.

Atlas Data Storage's $155 million seed round (May 2025) and AIRNA's $155 million series B (April 2025) are fueling next-gen RNA editing and CNS gene therapies.

Forecast Projection:

The Global Neurotherapeutics Market is poised for significant growth between 2025 and 2032. In 2024, the market maintained a steady upward trajectory, and with strategic initiatives by leading players accelerating adoption, the market is expected to soar throughout the forecast period. Companies leveraging these trends are well-positioned to capture emerging opportunities and maximize revenue potential.

Market Intelligence Research Process:

The Neurotherapeutics Market research report by DataM Intelligence combines primary and secondary data to deliver deep, actionable insights. It examines the full spectrum of factors shaping the industry, from government regulations and market conditions to competitive dynamics, historical trends, technological breakthroughs, upcoming innovations, and potential challenges. This comprehensive analysis not only highlights growth prospects but also identifies barriers, equipping businesses to navigate market volatility and capitalize on emerging opportunities.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=neurotherapeutics-market

Key Segmentation:

Neurological drugs lead the market with 58.73% share.

Neurological devices fastest-growing with 41.27% share.

By Type: (Oil-in-Water (O/W), Water-in-Oil (W/O), and Mixed Emulsions)

By Route of Administration: (Oral, Injectable, Topical / External, Rectal / Vaginal, and Others)

By Application: (Oncology, Cardiovascular, Neurology, Anti-Infectives, Dermatology, and Others)

By Distribution Channel: (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

Growth Drivers: The growing global burden of neurological disorders is fueling the neurotherapeutics market. Conditions like dementia, Parkinson's, epilepsy, and migraines affect billions worldwide, with developing countries seeing the fastest increases. Rising cases drive demand for novel drugs, biologics, and advanced device-based therapies such as Leqembi, Activa DBS, NeuroPace RNS, and CGRP inhibitors.

Restraints: High costs of treatments and devices limit market growth. Advanced drugs like Zolgensma and Spinraza, and procedures like DBS or NeuroPace RNS, are expensive, restricting access even in developed regions. These financial barriers slow adoption and long-term therapy adherence, constraining overall market expansion despite strong innovation.

Global Growth Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Latest Product Launches & Developments

Eisai and Biogen launched the Alzheimer's therapy LEQEMBI in Austria (August) and Germany (September 2025) for early-stage AD; EC approval granted in April 2025.

Medtronic's BrainSense Adaptive deep brain stimulation (aDBS) received FDA approval (February 2025), with new launches in Europe/US expanding minimally invasive neuromodulation for Parkinson's and chronic neurological disorders.

The FDA approved label expansion for donanemab (Kisulna, Eli Lilly) in early-stage Alzheimer's (July 2025); Exablate Neuro received approval for bilateral focused ultrasound in advanced Parkinson's disease.

Neurona Therapeutics advanced clinical trials of allogeneic neuronal cell therapies for chronic neurological disorders with $120M in new funding

In August 2025, Eisai Co., Ltd. and Biogen Inc. announced FDA approval of the Biologics License Application (BLA) for the once-weekly subcutaneous lecanemab-irmb injection, LEQEMBI IQLIK, for maintenance dosing in Alzheimer's patients with mild cognitive impairment (MCI) or early-stage dementia.

Meanwhile, neuromodulation devices are gaining traction. Spinal Cord Stimulation (SCS) and Vagus Nerve Stimulation (VNS), including LivaNova's VNS Therapy, are increasingly used for drug-resistant epilepsy and depression. The FDA-approved NeuroPace RNS offers a closed-loop system to detect and respond to abnormal brain activity, advancing personalized epilepsy treatment. Transcranial Magnetic Stimulation (TMS) devices like Neuronetics' NeuroStar and BrainsWay Deep TMS are expanding beyond depression to treat OCD and migraines.

Recent product launches continue to drive growth. In February 2025, Medtronic received FDA approval for BrainSense Adaptive Deep Brain Stimulation (aDBS) and BrainSense Electrode Identifier (EI). While neurological conditions like Parkinson's remain incurable, deep brain stimulation (DBS) has improved patient outcomes for over 30 years. DBS, similar to a cardiac pacemaker, uses a surgically implanted neurostimulator to deliver electrical signals to targeted brain regions, alleviating symptoms of debilitating neurological disorders.

Benefits of the Report:

Chapter 1 - Market Overview: Kickstarts the report with a comprehensive snapshot of the Neurotherapeutics Market, summarizing key segments by region, product type, and application. Highlights include market size, segment growth potential, and short- & long-term industry outlook.

Chapter 2 - Emerging Trends: Uncovers the game-changing trends and high-impact innovations shaping the future of the industry.

Chapter 3 - Competitive Landscape: Offers a deep dive into market competition, detailing revenue shares, strategic initiatives, and recent mergers & acquisitions.

Chapter 4 - Top Player Profiles: Features detailed company profiles, covering revenue, profit margins, product lines, and major milestones for leading market players.

Chapters 5 & 6 - Regional & Country Analysis: Breaks down revenue performance across global regions, providing insights on market sizes, opportunities, and growth prospects worldwide.

Chapter 7 - Segmentation Analysis: Explores market segmentation by type, revealing high-potential categories and guiding businesses towards lucrative areas.

Chapter 8 - Application Insights: Examines downstream markets and identifies promising sectors for expansion, showing how different applications are driving growth.

Chapter 9 - Supply Chain Mapping: Maps the entire industry supply chain, highlighting upstream and downstream activities for a holistic market perspective.

Chapter 10 - Key Takeaways: Concludes with critical insights and actionable strategies, equipping stakeholders to make informed decisions and stay ahead in the market.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/neurotherapeutics-market?kb
FAQ's

Q1: How fast is the Neurotherapeutics Market expected to grow in the coming years?

A: The market is forecast to expand at a robust CAGR of 4.9% between 2025 and 2032, signaling strong global growth and investment potential.

Q2: Which regions are dominating the Neurotherapeutics Market and which are fastest-growing?

A: North America leads neurotherapeutics with 44.09% share; APAC fastest-growing at 5.9% CAGR.

Q3: What factors are fueling the Neurotherapeutics Market's growth across regions?

A: Growth is propelled by increasing demand, strategic initiatives by key players, and untapped opportunities in emerging markets, helping companies maximize revenue potential.

Regional Trends

US Neurotherapeutics Market Trends

The US remains a key market for neurotherapeutics due to a high neurological disease burden: over 6 million Americans with Alzheimer's, 1 million+ with Parkinson's, and 3.4 million with epilepsy. FDA approvals have accelerated innovation, with Leqembi (lecanemab) becoming the first disease-modifying Alzheimer's therapy with traditional approval. In migraine care, CGRP inhibitors such as Aimovig, Ajovy, and Emgality rapidly gained traction.

On the device side, the US leads in neuromodulation therapies with FDA-cleared solutions like Medtronic's Activa DBS, Abbott's Infinity DBS, Boston Scientific's Vercise Genus, and NeuroPace RNS for epilepsy. Non-invasive devices like Cala Trio and gammaCore further highlight the US as a hub for advanced neurological interventions.

Europe Neurotherapeutics Market Trends

Europe's neurotherapeutics market is growing strongly due to an aging population and high disease prevalence, with over 10 million dementia cases and 1.2 million Parkinson's patients. Regulatory support from the EMA and European Commission has facilitated access to key drugs like donepezil, rivastigmine, memantine, and Parkinson's therapies such as levodopa, safinamide (Xadago), and rasagiline.

Recently, in August-September 2025, Eisai Co., Ltd. and Biogen Inc. launched LEQEMBI, an anti-amyloid beta monoclonal antibody, in Austria and Germany. EC approval was granted in April 2025, marking it as the first therapy targeting the underlying cause of Alzheimer's disease in adults with mild cognitive impairment or early dementia, highlighting Europe's commitment to innovative neurotherapeutics.

Request 2 Days Free Trials with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.